about repair biotechnologies
Repair Biotechnologies develops the Cholesterol Degrading Platform (CDP), allowing cells to safely break down a toxic excess of cholesterol, and thereby reverse the pathology of cholesterol- based conditions such as atherosclerosis and Non- alcoholic. The first (cardiovascular disease, 16%) and second (stroke, 11%) top causes of human mortality both result from atherosclerosis. The CDP has proven very successful in mice trials and the company is moving forward to human clinical trials in 2023.
